Yes it is. It's exactly what the article suggests:
---
... Naviaux and his team completed early clinical testing for suramin. ... Now, the researchers hope that by revealing the specific ATP-related pathways that are altered in autism, their work will help scientists develop more drugs that target these pathways to manage the symptoms of ASD.
"Suramin is just one drug that targets the cell danger response," he said. "Now that we're closely interrogating how metabolism changes in ASD, we could be at the beginning of a drug renaissance that will create new options for treatment that never existed before."
---
This study [literally] brought to you by Pannex Therapeutics, Yuva Biosciences, Kuzani, and Paxmedica, MaraBio Systems, Inc and undoubtedly numerous other big pharma interests that were able to keep the study at arm's length enough to avoid disclosure requirements. [1]
---
... Naviaux and his team completed early clinical testing for suramin. ... Now, the researchers hope that by revealing the specific ATP-related pathways that are altered in autism, their work will help scientists develop more drugs that target these pathways to manage the symptoms of ASD.
"Suramin is just one drug that targets the cell danger response," he said. "Now that we're closely interrogating how metabolism changes in ASD, we could be at the beginning of a drug renaissance that will create new options for treatment that never existed before."
---
This study [literally] brought to you by Pannex Therapeutics, Yuva Biosciences, Kuzani, and Paxmedica, MaraBio Systems, Inc and undoubtedly numerous other big pharma interests that were able to keep the study at arm's length enough to avoid disclosure requirements. [1]
[1] - https://www.nature.com/articles/s42003-024-06102-y#Sec36